Residues of insulin secretion differ at the different site of pancreatic cancer in spite of diabetes history

Residues of insulin secretion differ at the different site of pancreatic cancer in spite of diabetes history - Residues of insulin secretion differ at the different site of pancreatic cancer in spite of diabetes history

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000041682

Enrollment

Registered

2021-03-31

Start date

2020-05-12

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

diabetes, pancreatic cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Diabetic patients with pancreatic cancer

Exclusion criteria

Exclusion criteria: Patients who refused or could not be followed for pancreatic cancer

Design outcomes

Primary

Measure	Time frame
the levels of serum or urinary C-peptide immunoreactivity (CPR)	—

Secondary

Measure	Time frame
Age, sex, height, BMI, family history of diabetes mellitus, history of smoking alcohol, family history of malignant disease, duration of diabetes, HbA1c,weight loss and period, treatment (oral hypoglycemic agent or insulin treatment or both), tumor marker (CA19-9), tumor diameter, pancreatic cancer development site and cancer treatment	—

Countries

Japan

Contacts

Public ContactHirotaka Shichijo

Kyorin University School of Medicine Department of Diabetes, Endocrinology and Metabolism

hirotaka.shichijo0210@gmail.com0422475511

Outcome results